Home/Pipeline/Cannabics® RCC-33

Cannabics® RCC-33

Colorectal Cancer

PreclinicalPreparation of Pre-IND Meeting Package

Key Facts

Indication

Colorectal Cancer

Phase

Preclinical

Status

Preparation of Pre-IND Meeting Package

Company

CNBX Pharmaceuticals

About CNBX Pharmaceuticals

CNBX Pharmaceuticals is a clinical-stage biotech focused on discovering and developing cannabinoid-derived medicines for cancer and neuropsychiatric conditions. Its core strategy utilizes a proprietary drug discovery platform combining high-throughput screening and bioinformatics to identify potent cannabinoid formulations. The company's lead candidate, RCC-33 for colorectal cancer, is in late preclinical development, with a broader pipeline targeting melanoma, breast cancer, and neuropsychiatry. CNBX operates as a public entity, with its core R&D conducted through its Israeli subsidiary, Cannabics Pharmaceuticals.

View full company profile

Therapeutic Areas

Oncology Neuropsychiatry

Other Colorectal Cancer Drugs

Drug	Company	Phase	Status
CY-101 + Pembrolizumab	Cytovation	Phase 1/2	Initiate 1H-26
M9140	Merck KGaA	Phase 1/2	Active
Repositioned/Rerouted API	Reponex	Not Specified	Active
Leronlimab	CytoDyn	Phase 2	Phase in progress
EGFR inhibitor	Acellera	Pre-clinical	Hit Identification
VCR-036	Vicero Bio	Preclinical	Active
CBI-1214	Cartography Biosciences	Phase 1	Active
QL335	QLSF Biotherapeutics	Phase 1	Active
Colorectal Cancer Detection Partnership	Daisy Genomics	Research/Assay Development	Active
High Internalization ADC	Lytica Therapeutics	Preclinical	Active
Undisclosed Colorectal Program(s)	Tavanta Therapeutics	Phase 2	Active
KRAS AK™PCR Mutation Screen Kit	Akcell Biotech	Commercial	Active